2007 Award for Outstanding Contributions in a Selected Area of Research
Dr. Bennett is professor of pathology and laboratory medicine at the University of Pennsylvania and director of the metabolic disease laboratory at The Children’s Hospital of Philadelphia. He also holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology at The Children’s Hospital of Philadelphia. The main focus of Dr. Bennett’s research has been the investigation of inborn errors of mitochondrial energy metabolism with a special emphasis on disorders of fatty acid metabolism. He was among the first to describe the fatal clinical phenotype and the first to identify neonatal metabolite abnormalities in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency. These observations led to the expansion of newborn screening by tandem mass spectrometry, in which most newborns are now screened for MCAD deficiency and a number of other inborn errors of metabolism. He is currently studying the hyperinsulinism associated with deficiency of short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD), another enzyme of fatty acid oxidation. Dr. Bennett has also devoted 25 years to studying a group of untreatable and devastating inherited neurodegenerative diseases known collectively as Batten disease. He recently identified a novel anti-neuronal apoptosis pathway in one of these diseases, which may lead to the first rational therapeutic intervention. He has published more than 225 peer-reviewed scientific papers, reviews, and book chapters and has been involved with the organization of numerous national and international congresses. Dr. Bennett reviews manuscripts for more than 30 journals and is currently on the editorial boards of Clinical Chemistry Journal and Molecular Genetics and Metabolism.
2003 The Distinguished Scientist Award
Michael J. Bennett, PhD was honored with AACC's 2003 Distinguished Scientist Award.